Regeneron announces FDA approval for anti-VEGF Eylea to treat macular edema following CRVO

Regeneron Pharmaceuticals Inc (REGN, Tarrytown, New York) have announced the receipt of FDA approval for their VEGF trap eye product (Eylea; VTE; aflibercept) for the treatment of macular edema following central retinal vein occlusion (CRVO). According to the company, the approval of the drug was based on data from Phase 3 studies. This is the second approval for Eylea and is expected to further expand the choice of available treatment regimens for the treatment of macular edema following CRVO.